<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sat, 05 Dec 2009 10:27:23 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>The Deep, Inner Meaning Of Bank of America's (BAC) TARP Repayment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3688027</guid>
      <description><![CDATA[As expected, Bank of America (BAC) will repurchase its $45 billion TARP preferreds, funded in part by an additional $18.8 billion in &quot;common stock equivalents&quot;, $4.0 billion in asset sales, and $1.7 billion in restricted stock issued to employees in lieu of cash bonuses.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3688027>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 14:19:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BAC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFC</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3688027</link>
    </item>
    <item>
      <title>Forget Yesterday, It's All About Jobs</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3687896</guid>
      <description><![CDATA[Good morning. Stocks tanked in the last half-hour on Thursday and while the major news outlets attributed the decline to either profit taking or some trepidation in front of this morning's big Jobs report, we'd like to offer a little more substantial reason for the 85 point dive on an otherwise subdued day of trading.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3687896>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 13:21:30 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AKAM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AKS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVLT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FSLR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GPRO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNPR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MCK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRVL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NFLX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NVLS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TXN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">V</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VRSN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3687896</link>
    </item>
    <item>
      <title>Fed Balance Sheet Declines By $15 Billion After Improbable Reduction In MBS, Excess Reserves, Monetary Base Hit Record</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3686922</guid>
      <description><![CDATA[The Federal Reserve's balance sheet declined by $15 billion to $2,183 billion from the prior week, after the Fed presumably offloaded $2.7 billion in MBS: this is the first time since QE started that MBS holdings have declined. If anyone can tell us just who the idiots are who bought MBS from the Fed (and at what price), and who the even greater idiots are who are supposed to believe this, please send us an email.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3686922>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 04:14:41 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">FNM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FRE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3686922</link>
    </item>
    <item>
      <title>China Will Continue To Drive The Global Economic Recovery In 2010</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683989</guid>
      <description><![CDATA[China isn’t just leading the global economic recovery – it’s lapping the field.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683989>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 14:38:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GROW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VALE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683989</link>
    </item>
    <item>
      <title>Interesting Stat: How Much Private Sector GDP Is From Construction And Real Estate?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683785</guid>
      <description><![CDATA[Back in June, we discussed commercial real estate at length following attendance at a large real estate conference in NYC. Our tone was cautious and one question we wondered about was the percentage of GDP that real estate represents. We actually came across the answer back in August and meant to share then, but didn't get to it. Since the question/topic remains highly relevant to considering the potential negative economic drag from depressed real estate activity, we're sharing now -- the following table is from an 8/28/09 NYTs article, &quot;Construction That Fueled Growth in the Sun Belt Slows&quot;:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683785>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 13:15:56 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BNI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683785</link>
    </item>
    <item>
      <title>Credit Market Overview:  Dec 3, 2009</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683773</guid>
      <description><![CDATA[The credit crunch crisis of confidence which we appear to be crawling out of even though the debt and equity markets catapulted themselves higher earlier this year could be similarly argued to be a crisis that started in the credit markets which crunched confidence around the world as it could a collapse in confidence in the value of the securities investors held which corrupted the credit markets causing them to cease funding.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683773>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 12:59:02 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">XOM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683773</link>
    </item>
    <item>
      <title>Grab Some Northern Exposure With EWC</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3682040</guid>
      <description><![CDATA[Emerging markets are captivating investors again, but tidy profits aren’t always far away. Placing your bets on well-established global markets can also prove rewarding. That's why we're looking at Canada.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3682040>[More...]</a>]]></description>
      <pubDate>Wed, 02 Dec 2009 21:39:42 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RIMM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3682040</link>
    </item>
    <item>
      <title>Unemployment Struggling To Turn A Corner As Job Losses Mount In November</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3681965</guid>
      <description><![CDATA[U.S. job losses in the private sector slowed in November but still exceeded economists’ projections, a report by payroll-processing firm Automatic Data Processing (Nasdaq: ADP) indicated yesterday (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3681965>[More...]</a>]]></description>
      <pubDate>Wed, 02 Dec 2009 21:20:20 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ADP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3681965</link>
    </item>
    <item>
      <title>Why Barrick Closed Their Gold Hedge</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3681409</guid>
      <description><![CDATA[It sure looks like gold is going to close above $1,200 an ounce today in New York. And large open market purchases from central banks in China, India and Russia are only helping the price surge more. (Just one year ago, some of these same central banks were actually selling gold in an attempt to fill an annual 10,000-ton supply gap.)<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3681409>[More...]</a>]]></description>
      <pubDate>Wed, 02 Dec 2009 19:15:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PAAS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SLW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SSRI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3681409</link>
    </item>
    <item>
      <title>How To Profit From The 'Next' Dubai</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3679796</guid>
      <description><![CDATA[The Dubai World default is a matter of only $60 billion – mere peanuts when compared to other elements of the global financial crisis. It’s thus of concern only to those silly enough to invest in real estate there (and the European banks foolish enough to finance it.) For the rest of us, it is a useful reminder that sudden collapses don’t really come out of nowhere – they can be foreseen, and smart investors can plan for them.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3679796>[More...]</a>]]></description>
      <pubDate>Wed, 02 Dec 2009 13:51:42 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3679796</link>
    </item>
    <item>
      <title>Ym Biosciences Reports Fiscal Year End 2009 Operational and Financial  Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3506040</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;MISSISSAUGA, ON, Sept. 25 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009. &lt;/li&gt;&lt;li&gt;&quot;Just weeks ago we received clearance from the US Treasury Department to extend our US clinical program for nimotuzumab, permitting us to conduct trials in any cancer indication. &lt;/li&gt;&lt;li&gt;Obtaining this clearance will be a transformative event for nimotuzumab and highlights the significant efforts made by YM staff in fiscal 2009 to advance our lead drug in an aligned effort with our licensees,&quot; said David Allan, Chairman and CEO of YM BioSciences.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3506040>[More...]</a>]]></description>
      <pubDate>Fri, 25 Sep 2009 11:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">YMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3506040</link>
    </item>
    <item>
      <title>Ym Biosciences Reports Third Quarter 2009 Operational and Financial  Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3231824</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;MISSISSAUGA, ON, May 14 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the third quarter of fiscal 2009, ended March 31, 2009. &lt;/li&gt;&lt;li&gt;&quot;Just a few days ago we reported critically important data at the 100th AACR conference in Denver highlighting the mechanistic differences between nimotuzumab and the EGFR targeting antibody, Erbitux(R),&quot; said David Allan, Chairman and CEO of YM BioSciences. &lt;/li&gt;&lt;li&gt;With Erbitux(R) as the leading EGFR-targeting drug on the market and generating more than $1.5 billion in annual sales, these findings are profound and further define the significant opportunity for our lead product.&quot;&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3231824>[More...]</a>]]></description>
      <pubDate>Thu, 14 May 2009 11:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">YMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3231824</link>
    </item>
    <item>
      <title>Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3560797</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;New U.S. and Foreign Patents&lt;/li&gt;&lt;li&gt;The United States Patent and Trademark Office (USPTO) issued a patent to   HDC that includes additional, broader claims to the Company's exclusive   Recursive Feature Elimination (RFE) using Support Vector Machines   (&quot;SVM&quot;) or SVM-RFE method, the first patent for which issued in 2006.   &lt;/li&gt;&lt;li&gt;The European Patent Office issued a notice of its intent to grant a   patent covering HDC's SVM-based computer-aided image analysis   techniques.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3560797>[More...]</a>]]></description>
      <pubDate>Mon, 19 Oct 2009 13:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DGX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HDVY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IART</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3560797</link>
    </item>
    <item>
      <title>Safeguard Scientifics Announces Sale of 2.4 Million Additional Clarient Shares Pursuant to Overallotment Option</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3496832</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Safeguard   Scientifics, Inc. (NYSE:SFE), a holding company that builds value in   growth-stage life   sciences and technology   companies, today announced that it has sold an additional 2.4 million   shares of its position in Clarient,   Inc. (Nasdaq: CLRT) through a Clarient shelf registration on Form   S-3 that was declared effective by the Securities and Exchange   Commission on August 20, 2009. &lt;/li&gt;&lt;li&gt;Underwriters for the offering  -- Stephens   Inc., Robert W. Baird &amp; Co., Stifel, Nicolaus &amp; Company and Boenning &amp;   Scattergood  -- exercised an option to purchase the additional shares.&lt;/li&gt;&lt;li&gt;To date, Safeguard has sold approximately 18.4 million shares of   Clarient common stock and now holds 28.1 million shares and 2.75 million   warrants at various strike prices, with a combined market value of $131   million as of yesterday's close.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3496832>[More...]</a>]]></description>
      <pubDate>Tue, 22 Sep 2009 13:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3496832</link>
    </item>
    <item>
      <title>YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3404789</guid>
      <description><![CDATA[MISSISSAUGA, ON, Aug. 10 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3404789>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 10:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">YM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">YMI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">YMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3404789</link>
    </item>
    <item>
      <title>Safeguard Scientifics Announces Second Quarter 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3393891</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Safeguard   Scientifics, Inc. (NYSE: SFE), a holding company that builds value   in growth-stage life   sciences and technology   companies, today announced that consolidated net income from continuing   operations attributable to Safeguard common shareholders in the second   quarter was $146.2 million, or $1.20 per share, compared with a net loss   of $7.5 million, or $0.06 per share, in the same period of 2008.&lt;/li&gt;&lt;li&gt;Second quarter results reflect recognition of an unrealized gain in   income from continuing operations of $106.0 million stemming from the   deconsolidation of Safeguard's holdings in Clarient, Inc. (Nasdaq: CLRT)   and an additional gain of $52.5 million resulting from the   mark-to-market of Safeguard's holdings in Clarient as of June 30, 2009.   &lt;/li&gt;&lt;li&gt;The gains and corresponding increases in shareholders' equity are the   result of the reduction in Safeguard's percentage ownership in Clarient   (based on Clarient's recently completed private placement with Oak   Investment Partners) and Safeguard's election to account for its   retained interest in Clarient under the fair value option.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3393891>[More...]</a>]]></description>
      <pubDate>Wed, 05 Aug 2009 10:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3393891</link>
    </item>
    <item>
      <title>Clarient to Present at Canaccord Adams 29th Annual Global Growth Conference on Wednesday, August 12th</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3394202</guid>
      <description><![CDATA[Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the Canaccord Adams 29th Annual Global Growth Conference at 8:00 am EDT on Wednesday, August 12, 2009. The conference will be held at the InterContinental Boston Hotel, August 11-13, 2009.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3394202>[More...]</a>]]></description>
      <pubDate>Wed, 05 Aug 2009 09:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3394202</link>
    </item>
    <item>
      <title>Clarient Reports Second Quarter Revenue Up 40 Percent ; New Molecular Tests and Increased Case Volume Continue to Drive Revenue Growth; First Net Income Reported; Revenue Guidance Increased</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3393248</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;ALISO VIEJO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today reported financial results for the second quarter and six months ended June 30, 2009.  &lt;/li&gt;&lt;li&gt;Financial results included a 40 percent increase in revenue for the second quarter of 2009 versus the second quarter of 2008, and a 43 percent increase in revenue for this year's first six months versus the first six months of 2008.&lt;/li&gt;&lt;li&gt;Second quarter revenue was $23.7 million, compared to $16.9 million for the same period in 2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3393248>[More...]</a>]]></description>
      <pubDate>Tue, 04 Aug 2009 22:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3393248</link>
    </item>
    <item>
      <title>Clarient Reports Second Quarter Revenue Up 40 Percent</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3392637</guid>
      <description><![CDATA[Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today reported financial results for the second quarter and six months ended June 30, 2009. Financial results included a 40 percent increase in revenue for the second quarter of 2009 versus the second quarter of 2008, and a 43 percent increase in revenue for this year's first six months versus the first six months of 2008.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3392637>[More...]</a>]]></description>
      <pubDate>Tue, 04 Aug 2009 20:10:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3392637</link>
    </item>
    <item>
      <title>Clarient to Release 2009 Second Quarter Financial Results On Tuesday, August 4th</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3377517</guid>
      <description><![CDATA[Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the second quarter ended June 30, 2009 after the stock market closes on Tuesday, August 4th.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3377517>[More...]</a>]]></description>
      <pubDate>Tue, 28 Jul 2009 09:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3377517</link>
    </item>
    <item>
      <title>Emerging Growth Equities, Ltd. Initiates Coverage of Clarient, Inc. With a Buy Rating and $4.50 Price Target</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3365794</guid>
      <description><![CDATA[Emerging Growth Equities, Ltd. initiates coverage of Clarient, Inc. with a BUY rating and a $4.50 price target. Clarient is an advanced cancer diagnostic laboratory with outstanding long-term growth opportunity, in our view. Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies. Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 610-783-4797.This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security. Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. For these and other reasons, the investments discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Transactions in securities mentioned herein may be effected only in those states where such securities are qualified for sale. Any statements nonfactual in nature herein constitute only current opinions or estimates, represent only the current judgment of the author, and are subject to change without notice. This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from the results described in the forward-looking statements. Emerging Growth Equities, Ltd. or their partners, officers, directors, analysts, employees or customers may have an interest in the securities mentioned herein and may make purchases or sales as principal or agent of these securities, or their derivatives, while this report is in circulation. A partner, employee, analyst, officer, or director of Emerging Growth Equities, Ltd. may serve as a director or consultant for any company mentioned herein. Emerging Growth Equities, Ltd. may from time to time perform investment banking services for, or solicit investment banking business or other business from, any company mentioned herein. Additional information on the securities discussed herein is available on request. Copyright 2009 Emerging Growth Equities, Ltd.Emerging Growth Equities, Ltd. is a member of the Financial Industry Regulatory Authority, CRD number 47040.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3365794>[More...]</a>]]></description>
      <pubDate>Wed, 22 Jul 2009 14:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3365794</link>
    </item>
    <item>
      <title>Form  4          CLARIENT, INC             For: Dec 02  Filed by: Daly David (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3685529</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3685529>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 19:13:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3685529</link>
    </item>
    <item>
      <title>Form  4          CLARIENT, INC             For: Nov 05  Filed by: SAFEGUARD SCIENTIFICS INC (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611968</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611968>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 20:24:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611968</link>
    </item>
    <item>
      <title>Form  4          Daly David                For: Nov 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3606291</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3606291>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 17:21:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3606291</link>
    </item>
    <item>
      <title>Form  4          Daly David                For: Oct 05 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3529862</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3529862>[More...]</a>]]></description>
      <pubDate>Mon, 05 Oct 2009 23:42:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3529862</link>
    </item>
    <item>
      <title>Form  4          CLARIENT, INC             For: Sep 18  Filed by: SAFEGUARD SCIENTIFICS INC (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3491520</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3491520>[More...]</a>]]></description>
      <pubDate>Fri, 18 Sep 2009 19:16:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3491520</link>
    </item>
    <item>
      <title>Form  4          Daly David                For: Sep 03 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3459764</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3459764>[More...]</a>]]></description>
      <pubDate>Fri, 04 Sep 2009 19:17:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3459764</link>
    </item>
    <item>
      <title>Form  4          WALLER GREGORY D          For: May 13 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3410477</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3410477>[More...]</a>]]></description>
      <pubDate>Wed, 12 Aug 2009 19:05:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3410477</link>
    </item>
    <item>
      <title>Form  4          Smith Dennis M Jr         For: May 13 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3410473</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3410473>[More...]</a>]]></description>
      <pubDate>Wed, 12 Aug 2009 19:02:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3410473</link>
    </item>
    <item>
      <title>Form  4          CLARIENT, INC             For: Jul 30  Filed by: SAFEGUARD SCIENTIFICS INC (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3385580</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3385580>[More...]</a>]]></description>
      <pubDate>Fri, 31 Jul 2009 20:41:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3385580</link>
    </item>
    <item>
      <title>Form  4          Daly David                For: Jul 13 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3348838</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3348838>[More...]</a>]]></description>
      <pubDate>Tue, 14 Jul 2009 20:34:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLRT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3348838</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=CLRT,YMI," rel="self" type="application/rss+xml" />
  </channel>
</rss>